COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Arthralgia During Anastrozole Therapy for Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00323479
Recruitment Status : Completed
First Posted : May 9, 2006
Results First Posted : April 6, 2012
Last Update Posted : April 6, 2012
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to describe the joint symptoms and structural joint changes under anastrozole as adjuvant treatment in postmenopausal women with early breast cancer.

Condition or disease Intervention/treatment Phase
Early Breast Cancer Drug: Anastrozole Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 114 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicentre, Open Study Assessing Joint Disorders Under ARIMIDEX® (1mg/Day) as Adjuvant Treatment in Post Menopausal Women With Early Breast Cancer
Study Start Date : June 2006
Actual Primary Completion Date : January 2009
Actual Study Completion Date : January 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer
Drug Information available for: Anastrozole

Intervention Details:
  • Drug: Anastrozole
    1mg/Day oral
    Other Names:
    • ZD1033

Primary Outcome Measures :
  1. Number of Participants With New Events of Arthralgia [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Functional Index of Cochin at 12 Months in Patients Under Anastrozole. [ Time Frame: 12 months ]
    Functional index of cochin score (from 0 to 90) : sum up of 18 questions on activities involving hands (each question scored from 0 = yes without difficulties (best) to 5 = impossible (worst)) based on 99 patients due to missing values.

  2. Serum Collagen Degradation Type I - CTX-I at 12 Months in Patients Under Anastrozole [ Time Frame: 12 months ]
    Results are based on 97 patients due to missing values

  3. Kellgren and Lawrence Score at 12 Months in Patients Under Anastrozole [ Time Frame: 12 months ]
    X ray evaluation of arthritis in 30 articulations ; each articulation scored from (0 = no arthritis to 4 = severe arthritis) based on 92 patients due to missing values

  4. Synovial Membrane Thickness at 12 Months in Patients Under Anastrozole [ Time Frame: 12 months ]
    X ray assessment on hands and wrists based on 99 patients due to missing values

  5. Percentage of Participant With Therapeutic Maintenance Under Anastrozole [ Time Frame: 12 months ]
    Treatment compliance. results based on 109 patients due to missing values

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Post menopausal woman with a breast cancer and scheduled for an adjuvant treatment with anastrozole
  • WHO performance status 0, 1 or 2
  • Provision of written informed consent

Exclusion Criteria:

  • Recurrence of breast cancer, inflammatory rheumatism
  • treatment by chondromodulator, oral glucocorticoid, aromatase inhibitor, anti estrogen, Herceptin
  • Diabetes treated by insulin
  • Severe renal or hepatic disease
  • Known hypersensitivity to anastrozole

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00323479

Layout table for location information
Research Site
Bordeaux, France
Research Site
Caen, France
Research Site
Lyon, France
Research Site
Paris, France
Research Site
Poitiers, France
Sponsors and Collaborators
Layout table for investigator information
Study Director: AstraZeneca France Medical Director, MD AstraZeneca
Layout table for additonal information
Responsible Party: AstraZeneca Identifier: NCT00323479    
Other Study ID Numbers: D5392L00013
2005-00-5441-19 EUDRACT number
First Posted: May 9, 2006    Key Record Dates
Results First Posted: April 6, 2012
Last Update Posted: April 6, 2012
Last Verified: March 2012
Keywords provided by AstraZeneca:
breast cancer treatment
joint disorders
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs